Acorda Therapeutics Announces Completion Of Enrollment In Fampridine-SR Clinical Trial In Multiple Sclerosis And Expansion Of Sales Force For Zanaflex Capsules(TM)
HAWTHORNE, N.Y.--(BUSINESS WIRE)--March 3, 2006--Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today it has completed enrollment of its Phase 3 clinical trial of Fampridine-SR in multiple sclerosis. The study, which is based on a Special Protocol Assessment (SPA) issued by the Food and Drug Administration (FDA), is evaluating the safety and efficacy of Fampridine-SR in improving walking ability in people with MS. The primary outcome measure for the study is an improvement in walking ability; secondary outcomes include measurements of leg strength and muscle spasticity. Data from this trial are expected in the third quarter of 2006.